Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 56, Issue 3, Pages 1613-1615Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.05655-11
Keywords
-
Categories
Funding
- Cubist Pharmaceuticals, Inc.
Ask authors/readers for more resources
MICs of CB-183,315, a novel lipopeptide antibiotic, vancomycin, and metronidazole were determined for intestinal anaerobes and Enterobacteriaceae. The MIC(90)s for Gram-negative anaerobes were > 8,192, 8,192, and 4 mu g/ml for CB-183,315, vancomycin, and metronidazole, respectively. Against Enterobacteriaceae, the MIC(90)s were > 8,192 mu g/ml, 1,024 mu g/ml, and 1,024 mu g/ml, respectively. The CB-183,315 MIC90 for Clostridium difficile was 0.5 mu g/ml. Its lack of activity against normal fecal organisms makes it a promising new agent for treating C. difficile.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available